Madrigal Pharmaceuticals (MDGL) Goldman Sachs 45th Annual Global Healthcare Conference summary

Transition to commercialization and team building

• Built a highly experienced team focused on scaling for significant product growth.

• Established field teams in hepatology and gastroenterology to support launch.

• Secured FDA priority review and approvals in the U.S., with a file under review in Europe.

• Raised $1.1 billion in cash to support launch and future growth.

Scientific data and market positioning

• Presented 10 abstracts at EASL, including real-world data on rapid NASH progression and long-term efficacy.

• Three-year data showed 91% of patients had reversed or stabilized liver stiffness.

• Quality-of-life data and results in MetALD patients matched those in NASH.

• Rezdiffra's data is years ahead of competitors, supporting strong first-mover advantage.

Launch execution and physician engagement

• Launch is progressing as expected, with ongoing education for physicians and practices.

• Practices are adapting workflows to incorporate the new therapy, with increasing efficiency over time.

• 30% of covered commercial lives have access, targeting 80% by year-end.

• 75% of scripts are coming from the 6,000 target prescribers.